Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 3-drug anti-HIV therapy Clear all
Completed Not applicable Interventional

TechMPower: Advancing HIV/SUD Care and Service Delivery for People in Re-entry

NCT07088770
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Substance Abuse Disorder
Interventions
Community Coalition CLS Workgroup/Network of Providers, Tech-mediated Training and Service Delivery, Multidisciplinary Implementation Team with Champion, Tech-mediated Peer Navigation Enhanced Case management (NCM)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kingston, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Therapeutic Vaccination in Treated HIV Disease

NCT03606213
View directory record Official record
Conditions
HIV-1-infection
Interventions
PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000
Biological · Device
Lead sponsor
Steven Deeks
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Phase 1 Interventional

A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes

NCT00001005
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 7, 2026, 10:38 AM EDT
Recruiting Not applicable Interventional

Project neuroARTEMIS

NCT06814275
View directory record Official record
Conditions
Stimulant Use, Human Immunodeficiency Virus (HIV), Depression
Interventions
ARTEMIS, Contingency management for Antiretroviral (ARV) adherence
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 59 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Results available

Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis

NCT00108862
View directory record Official record
Conditions
HIV Infection, Tuberculosis
Interventions
Strategy: Immediate ART, Strategy: Deferred ART
Other
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
13 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs

NCT00016718
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine (ddI), Efavirenz (EFV), Emtricitabine (FTC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
90 Days to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
16
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

NCT00006604
View directory record Official record
Conditions
HIV Infections
Interventions
ATV, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
91 Days to 21 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
32
States / cities
Birmingham, Alabama • Alhambra, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Phase 1 Interventional

Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

NCT00503347
View directory record Official record
Conditions
Hepatitis C Virus, Hiv Infections
Interventions
bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Phase 4 Interventional

DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

NCT00116116
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
efavirenz, stavudine extended release, lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
10
States / cities
Bakersfield, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 7, 2026, 10:38 AM EDT
Terminated Phase 1 Interventional Results available

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02408861
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm, HIV-associated Cancers
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Not applicable Interventional

A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs

NCT00002308
View directory record Official record
Conditions
HIV Infections
Interventions
Stavudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 7, 2026, 10:38 AM EDT
Recruiting Not applicable Interventional

reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)

NCT05958017
View directory record Official record
Conditions
Stimulant Use Disorder, People Living With HIV
Interventions
reSET, Standard of care
Behavioral · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT

NCT00002436
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Zidovudine, Zalcitabine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Phase 3 Interventional

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients

NCT00050895
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Efavirenz, Stavudine, Zidovudine, Lamivudine, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
59
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 7, 2026, 10:38 AM EDT
Terminated Phase 2 Interventional Results available

Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

NCT06005610
View directory record Official record
Conditions
HIV I Infection
Interventions
Estradiol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Phase 4 Interventional

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

NCT04340388
View directory record Official record
Conditions
HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome
Interventions
Dolutegravir 50 MG, Antiretroviral/Anti HIV
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients

NCT00002211
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Delavirdine mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Peapack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

NCT00000922
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 7, 2026, 10:38 AM EDT
Terminated Not applicable Interventional

Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir

NCT00006326
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Delavirdine mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
0 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 10:38 AM EDT
Terminated Phase 2 Interventional Results available

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

NCT04480554
View directory record Official record
Conditions
Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation, Methadone, Buprenorphine, Naltrexone, Antiretroviral Treatment
Interventions
Methadone, Buprenorphine/naloxone, XR-Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy

NCT00004978
View directory record Official record
Conditions
HIV Infections
Interventions
Recombinant interleukin-2 (rIL-2)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
78
States / cities
Los Angeles, California • Mill Valley, California • Oakland, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx

NCT00071890
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin 2, HAART, Treatment interruption
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Oct 7, 2026, 10:38 AM EDT
Completed Not applicable Interventional

A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment

NCT00002216
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Abacavir sulfate, Amprenavir, Nelfinavir mesylate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 10:38 AM EDT
Not listed Phase 3 Interventional

Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)

NCT00004981
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Lamivudine/Zidovudine, Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 10:38 AM EDT